COMPLEMENT SPLIT PRODUCT C3D AS AN INDICATOR OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS

被引：27

作者：

ROTHER, E ^{[1
]}

LANG, B ^{[1
]}

COLDEWEY, R ^{[1
]}

HARTUNG, K ^{[1
]}

PETER, HH ^{[1
]}

机构：

[1] UNIV FREIBURG,MED CTR,DEPT RHEUMATOL & CLIN IMMUNOL,HUGSTETTERSTR 55,W-7800 FREIBURG,GERMANY

来源：

CLINICAL RHEUMATOLOGY | 1993年 / 12卷 / 01期

关键词：

SYSTEMIC LUPUS ERYTHEMATOSUS; COMPLEMENT C3 SPLIT PRODUCT C3D; DISEASE ACTIVITY;

D O I：

10.1007/BF02231555

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In order to investigate, if complement levels can be used as an indicator of clinical activity in systemic lupus erythematosus (SLE), levels of C3, C4, CH50, and C3d were measured in 79 patients, 41 with inactive, 31 with moderately active and 7 with severely active disease. Our study shows that C3d, and particularly the C3d/C3 ratio, provide sensitive markers for disease activity in SLE. Since C3d is a direct measurement of complement turnover, it reflects complement activation better than C3, C4 and CH50.

引用

页码：31 / 35

页数：5

共 26 条

[1]

Bourke B.E., Moss I.K., Maini R.N., Measurement of the complement C3 breakdown product C3d by rocket immunoelectropheresis, J Immunol Methods, 48, (1982)

[2]

Brandslund I., Sierstedt H.C., Svehag S.-E., Teisner B., Double-decker-rocket immunoelectrophoresis for direct quantification of complement C3 split products with C3d specificities in plasma, Journal of Immunological Methods, 44, (1981)

[3]

Charlesworth J.A., Willia D.G., Sherington E., Lachmann P.J., Peters D.K., Metabolic studies of the third component of complement and the glycine-rich beta-glycoprotein in patients with hypocomplementemia, J Clin Invest, 53, pp. 1578-1587, (1974)

[4]

Clough J.D., Chang R.K., Effectiveness of testing for anti-DNA and the complement components iC3b, Bb, and C4 in the assessment of activity of systemic lupus erythematosus, J Clin Lab Anal, 4, pp. 268-273, (1990)

[5]

Gewurz H., Suyehira L.A., Complement and immune complexes, Manual of Clinical Immunology, (1980)

[6]

Hartung K., Fontana A., Klar M., Krippner H., Jorgens K., Lang B., Peter H.H., Pichler W.J., Schendel D., Robin-Winn M., Deicher H., Association of class I, II, and III MHC gene products with systemic lupus erythematosus. Results of a Central European Multicenter Study, Rheumatol Int, 9, pp. 13-18, (1989)

[7]

Hopkins P., Belmont H.M., Buyon J., Phillips M., Weissmann G., Abraon S.B., Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis, Arthritis Rheum, 31, (1988)

[8]

Inman R.D., Fong J.K.K., Pussell B.A., Ryan P.J., Hughes G.R.V., The C1q binding assay in systemic lupus erythematosus: discordance with disease activity, Arthritis Rheum, 23, pp. 1282-1286, (1980)

[9]

Isenberg D.A., Colaco C.B., Dudeney C., Todd-Pokropek A., Snaith M.L., The relationship of anti-DNA antibody idiotypes and anti-cardiolipin antibodies to disease activity in systemic lupus erythematosus, Medicine, 65, pp. 46-55, (1986)

[10]

Isenberg D.A., Shoenfeld Y., Schwartz R.S., Multiple serological reactions and their relationship to clinical activity in systemic lupus erythematosus, Arthritis Rheum, 27, pp. 132-138, (1984)

← 1 2 3 →